Rexin G
Rexin-G is for patients who are diagnosed with cancer and have solid tumors that are no longer responding to standard cancer treatment, or have refused chemotheraphy as treatment for the cancer. Rexin-G is an anti-cancer drug that has gained accelerated approval under monitored release for all solid tumors considering to be resistant to standard chemotherapy from the Philippine Bureau of Food and Drugs.
Mechanism of Action of Rexin-G
A gene called cyclin G1 is known to promote cancer growth. In animal experiments, when we get rid of this cyclin G1 gene, the cancer cells grow much slower or even die. Rexin-G contains a designer killer cyclin G1 gene that prevents the cyclin G1 from working. The way we will get this killer gene into the cancer cells is to use a vehicle (vector) to carry the gene into the cells. The vehicle we are using is a modified virus that has been changed so that it seeks out the cancerous areas and is not likely to cause disease. We put the gene into the vector, and the vector carries the gene into cancer cells. When the gene gets into cancer cells, it becomes part of the cells' genes and tells the cancer cells to stop growing. In both animal and human studies, the Rexin-G vector has caused shrinkage and necrosis as well as disappearance of tumors by X-ray studies and/or by direct microscopic examination of the treated tumor nodules after surgical resection.
Budget Guideline
Infusion 3 times per week for 4 weeks = 12 infusions
(US$2,000 per bag times 12 infusions) $24,000.00
Typically, Rexin-G is administered on an outpatient basis (3) times per week for (4) weeks total. This is done through a simple IV line or port-a-cath. Blood and urine samples may be taken at the same time if necessary. This whole process typically takes about 1 hour total.
